Spravato (Esketamine)
Asian Journal of Nursing Education and Research August 15, 2023 DOI: 10.52711/2349-2996.2023.00048 (opens in new tab)
Summary
AI-generated from the abstractSpravato, containing esketamine, is a treatment for adults with treatment-resistant major depression, used alongside an SSRI or SNRI after at least two other treatments have failed. It is typically combined with psychological or behavioral therapy. The text describes depression as more than temporary sadness and positions Spravato as an option for those who have not responded to prior treatments.
Study at a glance
| Characteristics | Peer reviewed |
|---|---|
| Population | Adults with treatment-resistant major depression |
| Intervention | Spravato (esketamine) |
| Key finding | Spravato is used to treat adults with major depression that is resistant to treatment, in combination with an SSRI or SNRI, after at least two other treatments have failed. |
Abstract
Depression is more than feeling a little sad or "blue" for a few days. Antidepressant medications are used in the treatment of clinical depression, usually alongside other forms of therapy such as psychological or behavioral therapy. Spravato is a medicine used to treat adults with major depression that is resistant to treatment. (Bahr, 2019) It is used in combination with an SSRI or SNRI medicine (other antidepressants) when at least two other treatments have failed. Spravato contains the active substance esketamine.